Orion Oyj A
The answer first
Does Orion beat the market?
Yes, Orion has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 87% of Nordic stocks
- Quality97
- Value14
- Trend98
No. 15 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Orion keeps must grow about 14% a year for 10 years.
Max for seven days
Follow Orion with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Orion
Your first answer is free, no account needed.
Do you own Orion, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Orion and a few more. Free, no card.
Super Stock+44.6%In short
- Orion has risen 75.7% over the past year, including dividends.
- Overall, Orion ranks better than 87% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 35.7%. The price is 1.4% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 87% of Nordic stocks.
No. 15 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 13 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.11
- Asset turnoverSales divided by everything the company owns1.07
- Return on equityProfit divided by equity+47.1%
- Cash conversionOperating cash flow divided by profit0.74
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 119 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity9.9
- P/SPrice divided by sales6.4
- P/EPrice divided by earnings21.0
- P/CFPrice divided by operating cash flow28.3
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 5 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+29.7%
- 6 months+42.3%
- 9 months+50.5%
- 12 months+75.7%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Orion
6 funds we follow own Orion. The share is how much of the fund the stock makes up.
- Norway3
- Sweden3
- 1 ETF
From the funds' latest known holdings.
About Orion
Orion Oyj A is a company in healthcare, listed on Nasdaq Helsinki. The share trades in EUR. It has around 4,200 employees.
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for…


See the full analysis of Orion.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card